Use of FSH receptor ligands for diagnosis and therapy of cancer
The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.
1. A method for collecting imaging data, the method comprising administering a patient an imaging agent comprising a detectably labeled follicle stimulating hormone (FSH) receptor ligand; and collecting imaging data in said patient.
2. The method according to claim 1 , wherein the FSH receptor (FSHR) ligand is a detectably labeled anti-FSHR antibody.
3. The method according to claim 1 , wherein the FSH receptor (FSHR) ligand is detectably labeled FSH.
4. The method according to claim 1 , wherein the FSH receptor (FSHR) ligand is detectably labeled FSHR-binding aptamer.
5. A method for the treatment of cancer comprising the administration of (i) a FSH receptor (FSHR) blocking agent or (ii) a FSH receptor (FSHR) ligand which is coupled to an anti-tumor agent to an individual having cancer.
6. The method according to claim 5 , wherein the FSHR blocking agent is an anti-FSHR antibody that prevents FSH-induced signaling.
7. The method according to claim 5 , wherein the FSHR blocking agent is an agent that blocks FSHR expression or intracellular signaling.
8. The method according to claim 5 , wherein said cancer is selected from the group consisting of prostate, kidney, ovary, testis, lung, liver, pancreas, stomach, breast, colon, brain, and urinary bladder cancer.
9. The method according to claim 8 , wherein the prostate cancer is prostate adenocarcinoma.
10. A pharmaceutical composition comprising a FSH receptor (FSHR) ligand coupled to an anti-tumor agent.
11. An in vitro method for diagnosis or prognosis or therapy monitoring of a cancer, which method comprises detecting FSHR in a blood sample of a test subject, wherein the presence in circulating blood cells of FSHR, is indicative of a cancer.
12. The method according to claim 11 , wherein the blood sample is whole blood or a preparation of peripheral blood polymorphonuclear cells (PMNs).